Literature DB >> 2840485

Severe encephalopathy associated with ifosfamide administration in two children with metastatic tumors.

M A Gieron1, L S Barak, J Estrada.   

Abstract

We studied two children with recurrent cancer, who during treatment with ifosfamide developed severe encephalopathy characterized by coma of several days duration. Ifosfamide was used as a single drug without mesna as an uroprotector. A 1-hour infusion of ifosfamide (1.8 g/m2) was given on days one and two of a planned 5-day course. Encephalopathy was associated with severe electroencephalographic abnormalities, e.g. slowing in delta range in one patient and electrographic seizures in another. Both, clinical and electroencephalographic features of encephalopathy were reversible.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2840485     DOI: 10.1007/BF00163537

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  4 in total

1.  Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna.

Authors:  C B Pratt; A A Green; M E Horowitz; W H Meyer; E Etcubanas; E Douglass; F A Hayes; E Thompson; J Wilimas; M Igarashi
Journal:  J Clin Oncol       Date:  1986-08       Impact factor: 44.544

2.  Ifosfamide/mesa and encephalopathy.

Authors:  B M Cantwell; A L Harris
Journal:  Lancet       Date:  1985-03-30       Impact factor: 79.321

3.  Ifosfamide, mesna and vincristine in paediatric oncology.

Authors:  J de Kraker; P A Voûte
Journal:  Cancer Treat Rev       Date:  1983-09       Impact factor: 12.111

4.  A phase II study of ifosfamide in children with recurrent solid tumours.

Authors:  C R Pinkerton; H Rogers; C James; A Bowman; P R Barbor; O B Eden; J Pritchard
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

  4 in total
  3 in total

1.  2-Chloroacetaldehyde-induced cerebral glutathione depletion and neurotoxicity.

Authors:  C Sood; P J O'Brien
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 2.  Dosing and side-effects of ifosfamide plus mesna.

Authors:  W P Brade; K Herdrich; U Kachel-Fischer; C E Araujo
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

3.  A phase II study of every other day high-dose ifosfamide in pediatric brain tumors: a Pediatric Oncology Group Study.

Authors:  R L Heideman; E C Douglass; J A Langston; J P Krischer; P C Burger; E H Kovnar; L E Kun; H S Friedman; R Kadota
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.